CoChat

Dopamine Receptors Modulate Cytotoxicity of Natural Killer Cells via cAMP-PKA-CREB Signaling Pathway

Zhao, Wei, Huang, Yan, Liu, Zhan, Cao, Bei-Bei, Peng, Yu-Ping, Qiu, Yi-Hua · 2013 · PLoS ONE
Cited by 68

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Dopamine (DA), a neurotransmitter in the nervous system, has been shown to modulate immune function. We have previously reported that five subtypes of DA receptors, including D1R, D2R, D3R, D4R and D5R, are expressed in T lymphocytes and they are involved in regulation of T cells. However, roles of these DA receptor subtypes and their coupled signal-transduction pathway in modulation of natural killer (NK) cells still remain to be clarified. The spleen of mice was harvested and NK cells were isolated and purified by negative selection using magnetic activated cell sorting. After NK cells were incubated with various drugs for 4 h, flow cytometry measured cytotoxicity of NK cells against YAC-1 lymphoma cells. NK cells expressed the five subtypes of DA receptors at mRNA and protein levels. Activation of D1-like receptors (including D1R and D5R) with agonist SKF38393 enhanced NK cell cytotoxicity, but activation of D2-like receptors (including D2R, D3R and D4R) with agonist quinpirole attenuated NK cells. Simultaneously, SKF38393 elevated D1R and D5R expression, cAMP content, and phosphorylated cAMP-response element-binding (CREB) level in NK cells, while quinpirole reduced D3R and D4R expression, cAMP content, and phosphorylated CREB level in NK cells. These effects of SKF38393 were blocked by SCH23390, an antagonist of D1-like receptors, and quinpirole effects were abolished by haloperidol, an antagonist of D2-like receptors. In support these results, H89, an inhibitor of phosphokinase A (PKA), prevented the SKF38393-dependent enhancement of NK cells and forskolin, an activator of adenylyl cyclase (AC), counteracted the quinpirole-dependent suppression of NK cells. These findings show that DA receptor subtypes are involved in modulation of NK cells and suggest that D1-like receptors facilitate NK cells by stimulating D1R/D5R-cAMP-PKA-CREB signaling pathway and D2-like receptors suppress NK cells by inhibiting D3R/D4R-cAMP-PKA-CREB signaling pathway. The results may provide more targets of therapeutic strategy for neuroimmune diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0065860

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 37

  1. Y Huang, 2010, Roles of Dopamine Receptor Subtypes in Mediating Modulation of T Lymphocyte Function, Neuroendocrino Lett, 31, 101
  2. G Hasko, 2002, Dopamine suppresses IL-12 p40 production by lipopolysaccharide-stimulated macrophages via a beta-adrenoceptor-mediated mechanism, J Neuroimmunol, 122, 34, 10.1016/S0165-5728(01)00459-3 · DOI
  3. MC Ghosh, 2003, Dopamine inhibits cytokine release and expression of tyrosine kinases, Lck and Fyn in activated T cells, Int Immunopharmacol, 3, 1019, 10.1016/S1567-5769(03)00100-0 · DOI
  4. L Carr, 2003, In vivo administration of L-dopa or dopamine decreases the number of splenic IFN gamma-producing cells, J Neuroimmunol, 137, 87, 10.1016/S0165-5728(03)00047-X · DOI
  5. S Basu, 1992, Stimulation of NK activity in Ehrlich ascites carcinoma-bearing mice following dopamine treatment, Biog Amines, 8, 191
  6. MA Teunis, 2004, Reduced splenic natural killer cell activity in rats with hyperreactive dopaminergic system, Psychoneuroendocrinology, 29, 1058, 10.1016/j.psyneuen.2003.09.007 · DOI
  7. A Kavelaars, 2005, Changes in innate and acquired immune responses in mice with targeted deletion of dopamine transporter gene, J Neuroimmunol, 161, 162, 10.1016/j.jneuroim.2005.01.004 · DOI
  8. D Vallone, 2000, Structure and function of dopamine receptors, Neurosci Biobehav Rev, 24, 125, 10.1016/S0149-7634(99)00063-9 · DOI · Paper page
  9. JB Zawilska, 2003, Dopamine receptors–structure, characterization and function, Postepy Hig Med Dosw, 57, 293
  10. GP Kirillova, 2008, Dopamine receptors in human lymphocytes: Radioligand binding and quantitative RT-PCR assays, J Neurosci Methods, 174, 272, 10.1016/j.jneumeth.2008.07.018 · DOI
  11. F McKenna, 2002, Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study, J Neuroimmunol, 132, 34, 10.1016/S0165-5728(02)00280-1 · DOI · Paper page
  12. F Mignini, 2009, Dopamine, vesicular transporters and dopamine receptor expression and localization in rat thymus and spleen, J Neuroimmunol, 206, 5, 10.1016/j.jneuroim.2008.09.018 · DOI
  13. EJ Meredith, 2006, Dopamine targets cycling B cells independent of receptors/transporter for oxidative attack: Implications for non-Hodgkin’s lymphoma, Proc Natl Acad Sci, 103, 13485, 10.1073/pnas.0605993103 · DOI
  14. B Saha, 2001, Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4+ and CD8+ T cells in vitro: a receptor-mediated mechanism, Neuroimmunomodulation, 9, 23, 10.1159/000049004 · DOI
  15. M Cosentino, 2007, Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop, Blood, 109, 632, 10.1182/blood-2006-01-028423 · DOI · Paper page
  16. J Kipnis, 2004, Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration, J Neurosci, 24, 6133, 10.1523/JNEUROSCI.0600-04.2004 · DOI · Paper page
  17. MJ Besser, 2005, Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNF-alpha or both, J Neuroimmunol, 169, 161, 10.1016/j.jneuroim.2005.07.013 · DOI · Paper page
  18. R Pacheco, 2009, Role of dopamine in the physiology of T-cells and dendritic cells, J Neuroimmunol, 216, 8, 10.1016/j.jneuroim.2009.07.018 · DOI
  19. NG Papadopoulos, 1994, An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry, J Immunol Meth, 177, 101, 10.1016/0022-1759(94)90147-3 · DOI · Paper page
  20. T Ilani, 2004, Dopaminergic regulation of immune cells via D3 dopamine receptor: a pathway mediated by activated T cells, Faseb J, 18, 1600, 10.1096/fj.04-1652fje · DOI
  21. Y Watanab, 2006, Dopamine selectively induces migration and homing of naïve CD8+ T cells via dopamine receptor D3, J Immunol, 176, 848, 10.4049/jimmunol.176.2.848 · DOI · Paper page
  22. K Nakano, 2008, Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis, Biochem Biophys Res Commun, 373, 286, 10.1016/j.bbrc.2008.06.012 · DOI
  23. FJ Monsma Jr, 1990, Molecular cloning and expression of a D1 dopamine receptor linked to adenylyl cyclase activation, Proc Natl Acad Sci, 87, 6723, 10.1073/pnas.87.17.6723 · DOI · Paper page
  24. DM Jackson, 1994, Dopamine receptors: molecular biology, biochemistry and behavioural aspects, Pharmacol Ther, 64, 291, 10.1016/0163-7258(94)90041-8 · DOI · Paper page
  25. SW Robinson, 1997, Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor, Mol Pharmacol, 52, 508, 10.1124/mol.52.3.508 · DOI
  26. WD Yao, 2008, Dopaminergic Signaling in Dendritic Spines, Biochem Pharmacol, 75, 2055, 10.1016/j.bcp.2008.01.018 · DOI
  27. C Santanavanich, 2005, Dopamine receptor activation in bovine pinealocyte via a cAMP-dependent transcription pathway, J Pineal Res, 38, 170, 10.1111/j.1600-079X.2004.00189.x · doi:10.1111/j.1600-079x.2004.00189.x
  28. I Yujnovsky, 2006, Signaling mediated by the dopamine D2 receptor potentiates circadian regulation by CLOCK:BMAL1, Proc Natl Acad Sci, 103, 6386, 10.1073/pnas.0510691103 · DOI · Paper page
  29. Y Iizuka, 2007, Evidence that the BLOC-1 protein dysbindin modulates dopamine D2 receptor internalization and signaling but not D1 internalization, J Neurosci, 27, 12390, 10.1523/JNEUROSCI.1689-07.2007 · DOI
  30. JE de Leeuw van Weenen, 2010, The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells, Biochem Pharmacol, 79, 1827, 10.1016/j.bcp.2010.01.029 · DOI
  31. C Ramstad, 2000, cAMP-dependent protein kinase (PKA) inhibits T cell activation by phosphorylating ser-43 of raf-1 in the MAPK/ERK pathway, Cell Signal, 12, 557, 10.1016/S0898-6568(00)00097-8 · DOI
  32. Y Harada, 1999, Cyclic AMP inhibits the activity of c-Jun N-terminal kinase (JNKp46) but not JNKp55 and ERK2 in human helper T lymphocytes. Biochem, Biophys Res Commun, 266, 129, 10.1006/bbrc.1999.1783 · DOI
  33. T Vang, 2001, Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor, J Exp Med, 193, 497, 10.1084/jem.193.4.497 · DOI · Paper page
  34. MS Hershfield, 2005, New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency, Eur J Immunol, 35, 25, 10.1002/eji.200425738 · DOI · Paper page
  35. JL Jimenez, 2001, Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation, J Pharmacol Exp Ther, 299, 753
  36. GCh Beck, 2004, Clinical review: immunomodulatory effects of dopamine in general inflammation, Crit Care, 8, 485, 10.1186/cc2879 · DOI
  37. M Yang, 2003, Requirement of Gbetagamma and c-Src in D2 dopamine receptor-mediated nuclear factor-kappaB activation, Mol Pharmacol, 64, 447, 10.1124/mol.64.2.447 · doi:10.1124/mol.64.2.447

Cited by

See all 68

Metadata

Authors
Zhao, W., Huang, Y., Liu, Z., Cao, B.-B., Peng, Y.-P., & Qiu, Y.-H.
Venue
PLoS ONE
Published
2013-06-14
Volume
8
Issue
6
Pages
e65860
ISSN
1932-6203
Cited by
68
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.